Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.77EUR
15 Feb 2019
Change (% chg)

€0.02 (+0.73%)
Prev Close
€2.75
Open
€2.75
Day's High
€2.78
Day's Low
€2.74
Volume
11,165
Avg. Vol
39,975
52-wk High
€3.31
52-wk Low
€2.57

Latest Key Developments (Source: Significant Developments)

Transgene Completes Safety And Tolerability Assessment In Phase 1B Part Trial In Hpv-Positive Cancer Patients
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - TRANSGENE SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.ON TRACK WITH PHASE 2 PART OF STUDY: FIRST PATIENTS ENROLLED.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.  Full Article

Transgene Completes Safety And Tolerability Assessment Of TG4001
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Transgene SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.FIRST DATA FROM THIS TRIAL ON THE ACTIVITY OF THE COMBINATION ARE EXPECTED DURING THE SECOND HALF OF 2019..  Full Article

Transgene: Positive Results Of TG1050 Phase 1 Clinical Trial In Chronic Hepatitis B
Monday, 12 Nov 2018 

Nov 12 (Reuters) - TRANSGENE SA ::POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL OF TG1050 IN CHRONIC HEPATITIS B.PRIMARY END-POINT REACHED.TG1050 TRIGGERS T CELL-BASED IMMUNE RESPONSES.NEW PRECLINICAL DATA CLEARLY SUPPORT FURTHER INVESTIGATION OF TG1050 IN COMBINATION WITH ANTIVIRALS OR IMMUNOMODULATORS.NEW AND ENCOURAGING PRECLINICAL DATA SHOWING IMPROVED ANTIVIRAL ACTIVITY OF TG1050 WHEN ADMINISTERED IN COMBINATION WITH EITHER ANTIVIRALS OR IMMUNOMODULATORS IN HBV-PERSISTENT MICE.  Full Article

Transgene: Positive Results From Phase 1 Clinical Trial Of TG1050 In Chronic Hepatitis B
Monday, 12 Nov 2018 

Nov 12 (Reuters) - TRANSGENE SA ::TRANSGENE - POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL OF TG1050 IN CHRONIC HEPATITIS B PRESENTED AT THE AASLD LIVER MEETING 2018.PRIMARY END-POINT REACHED.NEW PRECLINICAL DATA CLEARLY SUPPORT FURTHER INVESTIGATION OF TG1050 IN COMBINATION WITH ANTIVIRALS OR IMMUNOMODULATORS.TG1050 TRIGGERS T CELL-BASED IMMUNE RESPONSES, SPECIFIC OF ALL 3 ENCODED HBV ANTIGENS, CONFIRMING THE MECHANISM OF ACTION OF THE PRODUCT.  Full Article

Transgene Presents Data Supporting Myvac Platform
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - TRANSGENE SA ::TRANSGENE PRESENTS FIRST PRECLINICAL AND TRANSLATIONAL DATA SUPPORTING ITS NOVEL MYVAC™ PLATFORM.SET UP PROCESS AIMED AT DEVELOPING A MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED, INDIVIDUALIZED IMMUNOTHERAPY PRODUCT THAT RECOGNIZES AND DESTROYS TUMORS.IMMUNOGENICITY OF INDIVIDUALIZED VACCINE HAS BEEN DEMONSTRATED IN A HUMANIZED MICE MODEL..IMMUNE RESPONSE OBSERVED IN MICE MODEL PARTLY OVERLAPS WITH ONE OBSERVED IN HUMANS.  Full Article

Transgene Q3 Operating Revenue Up At 37.5 Million Euros
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - TRANSGENE SA ::CASH, CASH EQUIVALENTS, AND OTHER CURRENT FINANCIAL ASSETS STOOD AT €26.6 MILLION AS OF SEPTEMBER 30, 2018.CASH BURN IN LINE WITH EXPECTATIONS - COMPANY CONFIRMS FINANCIAL VISIBILITY UNTIL SEPTEMBER 2019.Q3 OPERATING REVENUE EUR 37.5 MILLION VERSUS EUR 1.6 MILLION YEAR AGO.  Full Article

Transgene Sells Greater China Rights Of TG6002 And TG1050 To Tasly Biopharmaceuticals
Monday, 20 Aug 2018 

Aug 20 (Reuters) - TRANSGENE SA ::COMPLETES THE SALE OF GREATER CHINA RIGHTS OF TG6002 AND TG1050 TO TASLY BIOPHARMACEUTICALS FOR $48 MILLION IN NEWLY-ISSUED SHARES.T601 AND T101 ARE NOW BEING DEVELOPED BY TASLY BIOPHARMACEUTICALS FOR PATIENTS IN GREATER CHINA.27.4 MILLION NEWLY-ISSUED SHARES OF TASLY BIOPHARMACEUTICALS HAVE BEEN DELIVERED TO TRANSGENE.TRANSGENE NOW HOLDS APPROXIMATELY 2.53% OF OUTSTANDING CAPITAL OF TASLY BIOPHARMACEUTICALS.  Full Article

Transgene Collaborates with BioInvent To Treat Solid Tumors
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - TRANSGENE SA ::BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS.‍COLLABORATION'S RESEARCH AND DEVELOPMENT COSTS, AS WELL AS REVENUES AND ROYALTIES, WILL BE SHARED 50:50​.WILL CONTRIBUTE BOTH ITS OV DESIGN AND ENGINEERING EXPERTISE AS WELL AS ITS PROPRIETARY ENGINEERED VACCINIA VIRUS.  Full Article

Transgene successfully raises 14.4 million euros
Friday, 10 Nov 2017 

Nov 10 (Reuters) - TRANSGENE SA ::TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS.‍TRANSACTION WAS OVERSUBSCRIBED, AT EUR 2.55 PER SHARE​.‍NEW SHARES WILL HAVE A PAR VALUE OF ONE EURO EACH​.‍NEW SHARES CARRY DIVIDEND RIGHTS AS FROM THEIR ISSUE DATE​.‍NEW SHARES' ADMISSION TO TRADING EXPECTED TO OCCUR ON NOV 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene launches capital increase by accelerated book-build offering
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - TRANSGENE SA ::TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING.‍CAPITAL INCREASE WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS THROUGH ISSUANCE OF UP TO 5,643,199 ORDINARY SHARES​.‍TO ISSUE OF UP TO 5,643,199 ORDINARY SHARES OF COMPANY, REPRESENTING APPROXIMATELY 10% OF EXISTING ISSUED SHARE CAPITAL​.‍GROSS PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE APPROXIMATELY EUR 14 MILLION​.‍FUNDS RAISED WILL BE USED TO PURSUE CLINICAL AND PRECLINICAL DEVELOPMENT OF TRANSGENE'S INNOVATIVE IMMUNOTHERAPIES​.‍ADMISSION TO TRADING OF NEW SHARES EXPECTED TO OCCUR ON NOVEMBER 14, 2017 ON EURONEXT IN PARIS​.  Full Article

French and Benelux stocks-Factors to watch on August 21

Aug 21 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.